文献速递临床试验与 GCP流行病学与生物统计

对疑似子痫前期孕妇重复采样胎盘生长因子以减少不良围产结局的随机对照试验研究方案(PARROT-2)

Placental growth fActor Repeat sampling for Reduction of adverse perinatal Outcomes in women with suspecTed pre-eclampsia: study protocol for a randomised controlled trial (PARROT-2).
PubMed 文献 · Trials · 2022-09-02

PARROT-2为多中心随机对照试验,纳入孕22+0至35+6周疑似子痫前期孕妇,比较重复揭示与重复隐藏胎盘生长因子(PlGF)检测对围产期严重不良结局复合终点的影响,并评估成本效果。所有入组前均接受首次揭示性PlGF检测,后续按初始结果每周或每两周重复检测并随机分组。

要点

  • 疑似早产子痫前期孕妇首次就诊时推荐单次PlGF检测以帮助排除子痫前期。
  • 重复PlGF检测对母胎不良结局及成本效果的作用尚待研究。
  • PARROT-2比较重复揭示与重复隐藏PlGF检测对围产期严重不良结局的影响。

核心结论

  • 该试验旨在探究重复PlGF检测是否减少严重母胎不良结局以及是否具有成本效果。

研究设计与样本

  • 多中心随机对照试验,纳入孕22+0至35+6周疑似子痫前期的孕妇。
  • 所有孕妇入组前均接受首次揭示性PlGF检测,后续重复检测按初始结果每周或每两周进行,结果随机分为揭示组与隐藏组。
  • 主要目标为评估重复PlGF检测是否降低围产期严重不良结局复合终点(死产、早期新生儿死亡或新生儿病房入住)。

主要发现

  • 原文未报告结果。

关键数值与推荐

  • 国家指南推荐所有疑似早产子痫前期孕妇在首次怀疑患病时接受单次PlGF检测以帮助排除子痫前期。
  • 重复PlGF检测的临床与成本效果尚未被研究。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 重复PlGF检测对母胎不良结局的作用及成本效果尚待评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pre-eclampsia is a complex pregnancy disorder, characterised by new or worsening hypertension associated with multi-organ dysfunction. Adverse outcomes include eclampsia, liver rupture, stroke, pulmonary oedema, and acute kidney injury in the mother, and stillbirth, foetal growth restriction, and iatrogenic preterm delivery for the foetus. Angiogenic biomarkers, including placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1), have been identified as valuable biomarkers for preterm pre-eclampsia, accelerating diagnosis and reducing maternal adverse outcomes by risk stratification, with enhanced surveillance for high-risk women. PlGF-based testing for suspected preterm pre-eclampsia has been incorporated into national guidance. The role of repeat PlGF-based testing and its effect on maternal and perinatal adverse outcomes have yet to be evaluated. METHODS: The PARROT-2 trial is a multi-centre randomised controlled trial of repeat revealed PlGF-based testing compared to repeat concealed testing, in women presenting with suspected pre-eclampsia between 22+0 and 35+6 weeks' gestation. The primary objective is to establish whether repeat PlGF-based testing decreases a composite of perinatal severe adverse outcomes (stillbirth, early neonatal death, or neonatal unit admission). All women prior to enrolment in the trial will have an initial revealed PlGF-based test. Repeat PlGF-based tests will be performed weekly or two-weekly, depending on the initial PlGF-based test result, with results randomised to revealed or concealed. DISCUSSION: National guidance recommends that all women presenting with suspected preterm pre-eclampsia should have a single PlGF-based test when disease is first suspected, to help rule out pre-eclampsia. Clinical and cost-effectiveness of repeat PlGF-based testing has yet to be investigated. This trial aims to address whether repeat PlGF-based testing reduces severe maternal and perinatal adverse outcomes and whether repeat testing is cost-effective. TRIAL REGISTRATION: ISRCTN 85912420 . Registered on 25 November 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Hurrell A, Sparkes J, Duhig K, et al. Placental growth fActor Repeat sampling for Reduction of adverse perinatal Outcomes in women with suspecTed pre-eclampsia: study protocol for a randomised controlled trial (PARROT-2). Trials. 2022. PMID: 36056408. doi:10.1186/s13063-022-06652-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。